Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02112838 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
A Phase 2 study of IgA Nephropathy, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT02112838 is a Phase 2 study of IgA Nephropathy that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 76 participants, below the 160-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02112838, a Phase 2 study of IgA Nephropathy, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fostamatinib 150 mg
- DRUG Fostamatinib 100 mg
Study Locations (20)
Other
- Medical University Vienna, Nephrology - Vienna
- Queen Mary Hospital - Hong Kong
- China Medical University Hospital - Taichung
- School of Medicine, Chang Gung University, Chang Gung Memorial Hospital - Taoyuan District
- Addenbrookes Hospital - Cambridge
- Cardiff University - Cardiff
- Leicester General Hospital - Leicester
- Royal Free Hospital - London
- Hammersmith Hospital - London
- Freeman Hospital - Newcastle upon Tyne
California
- Stanford University Medical - Palo Alto
Georgia
- Nephrology Associates PC, University Hospital, Professional Center 1 - Augusta
Ohio
- Ohio State University - Columbus
Tennessee
- Southeast Renal Research Institute - Chattanooga
Styria
- Medical University of Graz - Graz
Baden-Wurtemberberg
- Medical University of Heidelberg - Heidelberg
Bavaria
- Klinikum der Universität München - Munich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-11-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02112838
The ClinicalTrials.gov registry entry for NCT02112838 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 160-participant average among 10 other IgA Nephropathy trials with a reported enrollment target (52% lower). The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with IgA Nephropathy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02112838 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02112838 about?
NCT02112838 is a clinical study titled "Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy". The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy
What is the current status of trial NCT02112838?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2014-10. Estimated completion is 2018-11-12.
What conditions does trial NCT02112838 study?
This clinical trial studies the following conditions: IgA Nephropathy.
What interventions are being tested in trial NCT02112838?
The interventions under investigation include: Placebo (DRUG), Fostamatinib 150 mg (DRUG), Fostamatinib 100 mg (DRUG).
Who is sponsoring clinical trial NCT02112838?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02112838 being conducted?
This trial has 20 study locations across California, Georgia, Ohio, Tennessee, Styria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgA Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
RECRUITING · Phase 2
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
COMPLETED · Phase 2
-
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
COMPLETED · Phase 2
-
Study of BHV-1400 in IgA Nephropathy
RECRUITING · Phase 1
-
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.